Rice Hall James & Associates’s Aimmune Therapeutics AIMT Stock Holding History

Rice Hall James & Associates’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-973,920	Closed	-$33.6M	–	310
2020 Q3	$33.6M	Sell	973,920 -119,224	-11%	-$2.54M	1.35%	23
2020 Q2	$18.3M	Buy	1,093,144 +110,660	+11%	+$1.88M	0.78%	42
2020 Q1	$14.2M	Buy	982,484 +257,053	+35%	+$6.57M	0.79%	41
2019 Q4	$24.3M	Sell	725,431 -26,927	-4%	-$753K	0.82%	32
2019 Q3	$15.8M	Buy	752,358 +82,798	+12%	+$1.69M	0.56%	70
2019 Q2	$13.9M	Buy	669,560 +158,851	+31%	+$3.27M	0.46%	85
2019 Q1	$11.4M	Buy	+510,709	New	+$12M	0.37%	97

Rice Hall James & Associates's AIMT Position: Q4 2020 in Review

Rice Hall James & Associates sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 973,920 shares — an estimated $33.6M sold.

Rice Hall James & Associates first reported a position in AIMT in Q1 2019 and held it in 7 quarters. The position peaked at $33.6M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Rice Hall James & Associates reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Rice Hall James & Associates sold 973,920 Aimmune Therapeutics shares in Q4 2020, an estimated $33.6M.
Rice Hall James & Associates first reported a position in Aimmune Therapeutics in Q1 2019 and held it in 7 quarters.
Rice Hall James & Associates's Aimmune Therapeutics position peaked at $33.6M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Rice Hall James & Associates's 13F filing for Q4 2020, filed 16 Feb 2021.